Memory Support System for Mild Cognitive Impairment

Phase-Based Progress Estimates
Mild Cognitive ImpairmentMemory Support System - Behavioral
All Sexes
What conditions do you have?

Study Summary

This trial is developing an adaptation of an evidence-based intervention, the Memory Support System, for French-speaking individuals with mild cognitive impairment and their care partners.

Eligible Conditions
  • Mild Cognitive Impairment

Treatment Effectiveness

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Baseline and at 8 week follow-up.

Week 8
Caregiver Burden Inventory Short-Form
Chronic Disease Self-efficacy Scale
Everyday Cognition questionnaire.
Functional Assessment Questionnaire
Quality of Life in Alzheimer Disease
State-Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project
Week 8
Center for Epidemiologic Studies Depression Scale
Week 8
Adherence to French Memory Support System Intervention

Trial Safety

Trial Design

1 Treatment Group

Memory Support System participants
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Memory Support System · No Placebo Group · N/A

Memory Support System participants
Experimental Group · 1 Intervention: Memory Support System · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug
Memory Support System

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and at 8 week follow-up.

Who is running the clinical trial?

Bruyere Research InstituteLead Sponsor
29 Previous Clinical Trials
2,019,965 Total Patients Enrolled
Ottawa Hospital Research InstituteOTHER
529 Previous Clinical Trials
2,511,936 Total Patients Enrolled
Neil W Thomas, MDPrincipal InvestigatorBruyere Research Institute
Octavio Santos, PhDPrincipal InvestigatorOttawa Hospital Research Institute, Bruyere Research Institute

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a diagnosis of MCI.
You have a care partner who is available to you at least 2 times a week.
You are not taking nootropic(s) for ≥ 3 months.